Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 26OTHER 24NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 18Lymphoid 18CNS 9Sarcoma 7Gastrointestinal 7Thoracic 6Genitourinary 6Other solid neoplasm 3Breast 3Head & Neck 2Gynecologic 2Plasma cell 1Myeloid 1Dermatologic 1

Conditions

Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 48Bortezomib 22Lenalidomide 20Cyclophosphamide 20daratumumab 18Calcium Dobesilate 15Melphalan 13Thalidomide 12carfilzomib 9pomalidomide 7Prednisone 7dexamethasone acetate 6dexamethasone 21-phosphate 6auricularum 6Peripheral Blood Stem Cell Transplantation 6Doxorubicin 6isatuximab 5Filgrastim 5Vincristine 4Interferon-alpha 3Etoposide 3selinexor 2sargramostim 2ixazomib 2elotuzumab 2cobimetinib 2belantamab mafodotin 2Steroids 2Stem Cell Transplantation 2Radiotherapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Specimen Handling × Plasma cell × Clear all
NCT06022939 2026-05-06

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

SWOG Cancer Research Network

Phase 3 Recruiting
338 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡